Biodol Therapeutics;INSERM (Institut National de la Santé et da la Recherche Médicale);Université de Montpellier
发明人:
Jean VALMIER,Cyril RIVAT,Pierre SOKOLOFF
申请号：
US16613859
公开号：
US20200171022A1
申请日:
2018.05.17
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Inventors have evaluated the effects of the FLT3 inhibitors on morphine analgesic potency, on tolerance to morphine analgesia and on morphine-induced mechanical pain hypersensitivity. When the FLT3 inhibitor was administered together with morphine, the amount of analgesic effect was higher than that produced by morphine alone. Repeated administration of morphine induced a progressive decrease in morphine-induced analgesia as showed by the decreased percentage of MPE in control animals. Intrathecal pre-treatment with an FLT3 inhibitor reduced the decrease in morphine analgesia. The administration of FLT3 inhibitors completely prevented both the development of morphine-induced pain hypersensitivity and morphine-revealed latent pain sensitization. Accordingly, the invention relates to an FLT3 inhibitor for increasing the efficacy of an opioid for its analgesic effect, and hereby reducing the opioid dose while maintaining the opioid efficacy in a subject suffering from pain in need thereof.
